TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01153425

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Bone Biopsy
Description: MRI technology allowing generation of 3D images with considerably smaller voxel size than previous technology through the use of novel pulse sequences and advanced interpolation techniques.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Bone Biopsy
Description: MRI technology allowing generation of 3D images with considerably smaller voxel size than previous technology through the use of novel pulse sequences and advanced interpolation techniques.
Study: NCT02579265

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid® 20%
Description: Dose: The targeted maximal dose is 3.0 g/kg/day. In patients already receiving parenteral nutrition (PN) before starting study treatment, the dose will either stay at 3.0 g/kg/day or be increased by 1.0 g/kg/day steps to a maximum of 3.0 g/kg/day.~Intralipid® 20% will be infused over 20 - 24 hours, as per hospital policy, at a weight based infusion rate.~Intralipid® 20% will be infused into a central or peripheral vein.
Study: NCT01153425

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide
Description: Participants are clinically indicated for treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic Acid
Description: Participants are clinically indicated for treatment.
Study: NCT02174848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone oral solution
Description: Deferiprone oral solution at a dosage of up to 15 mg per kilogram of body weight, twice a day
Study: NCT02037412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor - 180 mg loading and 90 mg bid maintenance for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel - 600 mg loading and 75 mg qd maintenance for 3 months
Study: NCT03229226

Intervention type: OTHER
Intervention: Verbal versus procedural assessment
Description: Faculty were assessed on both verbal and simulated performance of procedures.
Study: NCT04464850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous iron
Description: Iron sucrose will be given by continuous infusion for 1 hour during the last 1 hour of dialysis session. Iron sucrose will be given for 24 weeks during study period.~Serum ferritin will be monitored at 4, 12, and 24 weeks after randomization.~The dosage of intravenous iron will be adjusted according to serum ferritin levels as follows.~Serum ferritin \<500 mg/dl: iron sucrose 100 mg every 2 weeks Serum ferritin 500-800 mg/dl: iron sucrose 100 mg every 4 weeks Serum ferritin \>800 mg/dl: discontinue iron sucrose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral iron
Description: 1 tablet, three times a day, of iron fumarate will be prescribed for 24 weeks of study period.~The dosage of iron fumarate will be adjusted according to serum ferritin levels as follows.~Serum ferritin will be monitored at 4, 12, and 24 weeks after randomization.~Serum ferritin \<500 mg/dl: iron fumarate 200 mg three times daily Serum ferritin 500-800 mg/dl: iron fumarate 200 mg once daily Serum ferritin \>800 mg/dl: discontinue iron fumarate
Study: NCT01748201

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Joint lavage and viscosupplementation
Description: The joint will be washed until obtaining translucent liquid and not hemorrhagic. Then it will receive an intra-articular injection of 6ml of hyaluronic acid (Synvisc One), 1ml of triamcinolone and 2 ml of ropivacaine.
Study: NCT00778388

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IC43
Description: The study consists of a screening visit within 14 days before the administration of the investigational medicinal product (IMP), an experimental part of 180 days with seven outpatient visits on days 0, 3, 7, 14, 28, 90 and 180 and with vaccinations on days 0 and 7. IC43 vaccine will be administered intramuscularly during study visit 0 and 7 at three different doses, adjuvanted with Al(OH)3, or in one dose without Al(OH)3. Injection volumes will be 0.5 mL, 1 mL or 2 mL. Placebo will be administered intramuscularly at a dosage of 1 mL.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IC43
Description: The study consists of a screening visit within 14 days before the administration of the investigational medicinal product (IMP), an experimental part of 180 days with seven outpatient visits on days 0, 3, 7, 14, 28, 90 and 180 and with vaccinations on days 0 and 7. IC43 vaccine will be administered intramuscularly during study visit 0 and 7 at three different doses, adjuvanted with Al(OH)3, or in one dose without Al(OH)3. Injection volumes will be 0.5 mL, 1 mL or 2 mL. Placebo will be administered intramuscularly at a dosage of 1 mL.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IC43
Description: The study consists of a screening visit within 14 days before the administration of the investigational medicinal product (IMP), an experimental part of 180 days with seven outpatient visits on days 0, 3, 7, 14, 28, 90 and 180 and with vaccinations on days 0 and 7. IC43 vaccine will be administered intramuscularly during study visit 0 and 7 at three different doses, adjuvanted with Al(OH)3, or in one dose without Al(OH)3. Injection volumes will be 0.5 mL, 1 mL or 2 mL. Placebo will be administered intramuscularly at a dosage of 1 mL.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IC43
Description: The study consists of a screening visit within 14 days before the administration of the investigational medicinal product (IMP), an experimental part of 180 days with seven outpatient visits on days 0, 3, 7, 14, 28, 90 and 180 and with vaccinations on days 0 and 7. IC43 vaccine will be administered intramuscularly during study visit 0 and 7 at three different doses, adjuvanted with Al(OH)3, or in one dose without Al(OH)3. Injection volumes will be 0.5 mL, 1 mL or 2 mL. Placebo will be administered intramuscularly at a dosage of 1 mL.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The study consists of a screening visit within 14 days before the administration of the investigational medicinal product (IMP), an experimental part of 180 days with seven outpatient visits on days 0, 3, 7, 14, 28, 90 and 180 and with vaccinations on days 0 and 7. IC43 vaccine will be administered intramuscularly during study visit 0 and 7 at three different doses, adjuvanted with Al(OH)3, or in one dose without Al(OH)3. Injection volumes will be 0.5 mL, 1 mL or 2 mL. Placebo will be administered intramuscularly at a dosage of 1 mL.
Study: NCT01517282

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MOR103
Description: Anti-GM-CSF monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MOR103
Description: Anti-GM-CSF monoclonal antibody

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to anti-GM-CSF monoclonal antibody
Study: NCT03717935

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Essential Amino Acid (EAA) Supplement
Description: Powder supplement

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Powder that will be similar to the essential amino acid supplement
Study: NCT02039193

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: CBT-manual (Zinbarg et al., 2006): Traditional cognitive-behavioral therapy (CBT) for GAD typically consists of psycho education of generalized anxiety disorder, relaxation training (RT), cognitive restructuring (CR) and with some in-vivo situational exposure for patients with overt behavioral avoidance (e.g., Barlow, Rapee, \& Brown, 1992; Borkovec \& Costello, 1993). Furthermore, imagery exposure as a GAD-specific form of in-sensu exposition will be applied to reduce experiential avoidance based on a well-introduced CBT-manual (Zinbarg et al., 2006). The manualized therapy follows an usual treatment format of 14 sessions to 50 minutes and a booster session after 6-months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: CBT-manual (Zinbarg et al., 2006): Traditional cognitive-behavioral therapy (CBT) for GAD typically consists of psycho education of generalized anxiety disorder, relaxation training (RT), cognitive restructuring (CR) and with some in-vivo situational exposure for patients with overt behavioral avoidance (e.g., Barlow, Rapee, \& Brown, 1992; Borkovec \& Costello, 1993). Furthermore, imagery exposure as a GAD-specific form of in-sensu exposition will be applied to reduce experiential avoidance based on a well-introduced CBT-manual (Zinbarg et al., 2006). The manualized therapy follows an usual treatment format of 14 sessions to 50 minutes and a booster session after 6-months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: CBT-manual (Zinbarg et al., 2006): Traditional cognitive-behavioral therapy (CBT) for GAD typically consists of psycho education of generalized anxiety disorder, relaxation training (RT), cognitive restructuring (CR) and with some in-vivo situational exposure for patients with overt behavioral avoidance (e.g., Barlow, Rapee, \& Brown, 1992; Borkovec \& Costello, 1993). Furthermore, imagery exposure as a GAD-specific form of in-sensu exposition will be applied to reduce experiential avoidance based on a well-introduced CBT-manual (Zinbarg et al., 2006). The manualized therapy follows an usual treatment format of 14 sessions to 50 minutes and a booster session after 6-months.
Study: NCT03074344

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XLHA+CoQ10
Description: XLHA+CoQ10 for four times a day for 12 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid (HA)
Description: Hyaluronic acid (HA) for four times a day for 12 weeks.
Study: NCT01609868

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Powder protein modular
Description: Infants will receive powder protein modular to achieve 4 grm/kg/day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liquid protein modular
Description: Infants will receive a commerically avaliable liquid protein modular to provide 4 grm/kg/day
Study: NCT01565889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: Sofosbuvir (SOF) 400 mg (1 × 400 mg tablet or 2 × 200 mg tablets) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: Sofosbuvir (SOF) 400 mg (1 × 400 mg tablet or 2 × 200 mg tablets) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: Sofosbuvir (SOF) 400 mg (1 × 400 mg tablet or 2 × 200 mg tablets) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: Sofosbuvir (SOF) 400 mg (1 × 400 mg tablet or 2 × 200 mg tablets) administered orally once daily
Study: NCT03425812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: To withdraw NSAIDs therapy
Description: NSAIDs therapy will be withdrew after washout period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: To continue NSAIDs therapy
Description: NSAIDs therapy will be continued.
Study: NCT01565889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: Sofosbuvir (SOF) 400 mg (1 × 400 mg tablet or 2 × 200 mg tablets) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: Sofosbuvir (SOF) 400 mg (1 × 400 mg tablet or 2 × 200 mg tablets) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EFV/FTC/TDF
Description: Efavirenz (EFV) 600 mg/emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination (FDC) tablet administered orally once daily
Study: NCT02342483

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MSM

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MSM

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MSM
Study: NCT01565889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EFV
Description: Efavirenz (EFV) 600 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZDV/3TC
Description: Zidovudine (ZDV) 300 mg/lamivudine (3TC) 150 mg FDC tablet administered orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATV
Description: Atazanavir (ATV) 400 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir (RTV) 100 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir (RTV) 100 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TDF
Description: FTC/TDF (200/300 mg) FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TDF
Description: FTC/TDF (200/300 mg) FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TDF
Description: FTC/TDF (200/300 mg) FDC tablet administered orally once daily
Study: NCT02243878

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy (16 Gray or Sham)
Description: Participants will be allocated in a 2:1 ratio to either 16 Gray SRT (IRay, Oraya, Newark,USA) delivered in a single session, or sham SRT.

Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: Stereotactic radiotherapy (16 Gray or Sham)
Description: Participants will be allocated in a 2:1 ratio to either 16 Gray SRT (IRay, Oraya, Newark,USA) delivered in a single session, or sham SRT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab
Description: Both arms will receive intravitreal injections of 0.5 mg ranibizumab at baseline, and then administered 'as required' (PRN) up to monthly, if predefined retreatment criteria are met.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 0.5 mg ranibizumab
Description: Both arms will receive intravitreal injections of 0.5 mg ranibizumab at baseline, and then administered 'as required' (PRN) up to monthly, if predefined retreatment criteria are met.
Study: NCT03335982

Intervention type: PROCEDURE
Group type: OTHER
Intervention: transendoscopic enteral tubing in mid-gut
Description: A TET tube was inserted into mid-gut through the nasal orifice and fixed on the pylorus wall by one tiny titanium endoscopic clip under anesthesia.
Study: NCT02515942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLG561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLG561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFG316

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: Empty syringe (without a needle) placed against the eye
Study: NCT02338869

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialogue-based psychosocial rehabilitation
Study: NCT04357210

Intervention type: PROCEDURE
Intervention: fistula tract excision and anal sphincter reconstruction
Description: The primary fistulous tract was excised together with any secondary tracts or residual cavities. Then on of the reconstructive steps was performed

Intervention type: PROCEDURE
Intervention: fistula tract excision and anal sphincter reconstruction
Description: The primary fistulous tract was excised together with any secondary tracts or residual cavities. Then on of the reconstructive steps was performed

Intervention type: PROCEDURE
Intervention: fistula tract excision and anal sphincter reconstruction
Description: The primary fistulous tract was excised together with any secondary tracts or residual cavities. Then on of the reconstructive steps was performed
Study: NCT03740425

Intervention type: PROCEDURE
Intervention: Blood Transfusion
Description: Blood Transfusion in patients who underwent transcatheter aortic valve implantation (TAVI)

Intervention type: PROCEDURE
Intervention: Blood Transfusion
Description: Blood Transfusion in patients who underwent transcatheter aortic valve implantation (TAVI)
Study: NCT04882007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSE-127
Description: mAb antagonist to CD127 receptor (or IL-7Rα)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSE-127
Description: mAb antagonist to CD127 receptor (or IL-7Rα)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSE-127
Description: mAb antagonist to CD127 receptor (or IL-7Rα)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline
Study: NCT04055688

Intervention type: DEVICE
Intervention: Orbeye surgical videomicroscope
Description: The ORBEYE surgical microscope is an FDA-cleared apparatus designed to facilitate operating procedures that involve fine nerves, blood vessels, and other small anatomic features by providing an enlarged stereoscopic visual field of the surgical site. The 4K 3D digital images of the ORBEYE microscope provide high-resolution stereoscopic images of the fine structures of tissue and blood vessels. As the surgical procedures are displayed on a large 55-inch monitor, the device is expected to reduce fatigue of the operator by eliminating the need for extensive viewing via microscope eyepieces for an extended period of time. The technology adopted in the ORBEYE was developed by Sony Olympus Medical Solutions, and its product design was handled by Olympus Medical Systems Corp. The ORBEYE is marketed by the Olympus Corporation.

Intervention type: DRUG
Intervention: 5-Aminolevulinic Acid
Description: 5- aminolevulinic acid (5-ALA) is a European Medicines Agency- and Food and Drug Administration- (FDA-) approved drug that is administered to patients 2 to 4 hours before surgery and converted preferentially by tumor cells to protoporphyrrin IX (PPIX). PPIX fluoresces red when exposed to blue light. Use of 5-ALA has previously been shown to permit surgeons to obtain a more complete tumor resection, and its use has also been associated with an increased rate of progression-free survival.(3) There are currently 2 surgical microscope systems available on the market that are equipped with a 5-ALA visualization system. These visualization systems are currently classified by the FDA as Class I-exempt accessories to Class I-cleared surgical microscopes.
Study: NCT02450227

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Spinach - Whole leaf (10 mg lutein)
Description: Identical spinach meals processed in two different ways by Frigodan, served alone or together with habitual diet

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Spinach - Whole leaf (10 mg lutein)
Description: Identical spinach meals processed in two different ways by Frigodan, served alone or together with habitual diet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Spinach - Minced (10 mg/lutein)
Description: Identical spinach meals processed in two different ways by Frigodan, served alone or together with habitual diet

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Spinach - Minced (10 mg/lutein)
Description: Identical spinach meals processed in two different ways by Frigodan, served alone or together with habitual diet
Study: NCT02666183

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video-C
Description: use videoconferencing to provide personalized information aimed at enhancing self -efficacy and providing emotional support for distant caregivers of patients with advanced cancers

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video-C
Description: use videoconferencing to provide personalized information aimed at enhancing self -efficacy and providing emotional support for distant caregivers of patients with advanced cancers

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse Coaching
Description: structured conversations with registered nurses aimed at providing emotional support

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Web-Only
Description: Access to a website with caregiving resources, resources for distant care givers, and cancer information
Study: NCT02280174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linagliptin
Description: linagliptin 5 mg/d for12 weeks
Study: NCT01433107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbinafine
Description: 1% single application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Terbinafine Placebo
Description: single application
Study: NCT01565889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRV
Description: Darunavir (DRV) 800 mg (2 × 400 mg tablets) administered orally once daily
Study: NCT01665274

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 1,000 mg/m² twice daily, d1-14, q3w
Study: NCT01347515

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: olive oil
Description: Each volunteer will be given, in random order, a single dose of 30 ml on a base of 80 g bread, of the following functional olive oils (FOO): FOO750 ppm, FOO500 ppm, which are enriched with two different amounts of broad-spectrum phenolic compounds from the virgin FOO250 ppm; all prepared at the Universitat de Lleida.~Post-ingestion the volunteers will rest for 8h in a comfortable warm room. During the run-in period of 2 weeks prior the first postprandial study and 1 week between each FOO treatment period, all subjects will undergo a 2-day pre-treatment wash-out period of a phenol-free diet (saturated fatty acids in the diet will be 10-13% of energy in an isocaloric diet). Volunteers will avoid non-essential physical activity during the 3 days prior to the treatment day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: olive oil
Description: Each volunteer will be given, in random order, a single dose of 30 ml on a base of 80 g bread, of the following functional olive oils (FOO): FOO750 ppm, FOO500 ppm, which are enriched with two different amounts of broad-spectrum phenolic compounds from the virgin FOO250 ppm; all prepared at the Universitat de Lleida.~Post-ingestion the volunteers will rest for 8h in a comfortable warm room. During the run-in period of 2 weeks prior the first postprandial study and 1 week between each FOO treatment period, all subjects will undergo a 2-day pre-treatment wash-out period of a phenol-free diet (saturated fatty acids in the diet will be 10-13% of energy in an isocaloric diet). Volunteers will avoid non-essential physical activity during the 3 days prior to the treatment day.
Study: NCT01565889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAL
Description: Raltegravir (RAL) 400 mg administered administered orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG
Description: Pegylated interferon alfa (PEG) 180 μg administered once weekly by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)